CancerDrs Find care

Head and Neck Cancer clinical trials in Virginia

46 actively recruiting head and neck cancer trials at 16 sites across Virginia.

Data from ClinicalTrials.gov · last refreshed

Phase 3 Recruiting NIH

Testing the Addition of an Immunotherapy Drug, Cemiplimab (REGN2810), Plus Surgery to the Usual Surgery Alone for Treating Advanced Skin Cancer

This phase III trial compares the effect of adding cemiplimab to standard therapy (surgery with or without radiation) versus standard therapy alone in treating patients with stage III/IV squamous cell skin cancer that is able to be removed…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06568172
Sites in Virginia:
  • University of Virginia Cancer Center — Charlottesville, Virginia
  • Inova Schar Cancer Institute — Fairfax, Virginia
  • VCU Massey Comprehensive Cancer Center — Richmond, Virginia
View on ClinicalTrials.gov →
Phase 3 Recruiting NIH

Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment

This phase III trial compares the effect of adding cetuximab to pembrolizumab versus pembrolizumab alone in treating patients with head and neck squamous cell carcinoma (HNSCC) that has come back after a period of improvement (recurrent) a…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06589804
Sites in Virginia:
  • VCU Massey Cancer Center at Stony Point — Richmond, Virginia
  • VCU Massey Comprehensive Cancer Center — Richmond, Virginia
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Phase 3 Study to Evaluate Petosemtamab Compared With Investigator's Choice Monotherapy in Previously Treated Head and Neck Squamous Cell Carcinoma Patients

This is a phase 3 open-label, randomized, controlled, multicenter study to compare petosemtamab vs investigator's choice monotherapy in HNSCC patients for the second- and third-line treatment of incurable metastatic/recurrent disease.

Sponsor: Merus B.V.
NCT ID: NCT06496178
Sites in Virginia:
  • Site 10 — Blacksburg, Virginia
  • Site 22 — Charlottesville, Virginia
  • Site 156 — Winchester, Virginia
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Phase 3 Study to Evaluate Petosemtamab Plus Pembrolizumab vs Pembrolizumab in First-line Treatment of Head and Neck Cancer (LiGeR - HN1)

This is a Phase 3 randomized, open-label study to evaluate the efficacy and safety of petosemtamab plus pembrolizumab vs pembrolizumab in first-line treatment of recurrent or metastatic PD-L1+ head and neck squamous cell carcinoma.

Sponsor: Merus B.V.
NCT ID: NCT06525220
Sites in Virginia:
  • Site 12 — Blacksburg, Virginia
  • Site 23 — Norfolk, Virginia
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma

The goal of this study is to assess the safety and effectiveness of Dostarlimab compared to Placebo in adult participants with Head and Neck Squamous Cell Carcinoma (HNSCC)

Sponsor: GlaxoSmithKline
NCT ID: NCT06256588
Sites in Virginia:
  • GSK Investigational Site — Fredericksburg, Virginia
  • GSK Investigational Site — Wytheville, Virginia
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma

The purpose of this study is to compare the efficacy and safety of ficlatuzumab plus cetuximab compared to placebo plus cetuximab in participants with recurrent/metastatic (R/M) HPV-negative Head and Neck Cancer. The primary hypothesis is …

Sponsor: AVEO Pharmaceuticals, Inc.
NCT ID: NCT06064877
Sites in Virginia:
  • VCU Massey Cancer Center — Richmond, Virginia
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

JNJ-90301900 (NBTXR3) Activated by Radiotherapy With or Without Cetuximab in LA-HNSCC

This is a global, open-label, randomized, 2-arm, Investigator's choice Phase 3 (Pivotal Stage) study to investigate the efficacy and safety of JNJ-90301900 (NBTXR3) / radiation therapy (RT)±cetuximab versus RT±cetuximab in treatment-naïve,…

Sponsor: Johnson & Johnson Enterprise Innovation Inc.
NCT ID: NCT04892173
Sites in Virginia:
  • University of Virginia — Charlottesville, Virginia
  • Macon Joan Brock Virginia Health Sciences Eastern Virginia Medical Group at Old Dominion University — Norfolk, Virginia
View on ClinicalTrials.gov →
Phase 2 Recruiting Network

Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery

This phase II trial studies how well radiation therapy with or without cisplatin works in treating patients with stage III-IVA squamous cell carcinoma of the head and neck who have undergone surgery. Radiation therapy uses high energy x-ra…

Sponsor: ECOG-ACRIN Cancer Research Group
NCT ID: NCT02734537
Sites in Virginia:
  • University of Virginia Cancer Center — Charlottesville, Virginia
  • Inova Schar Cancer Institute — Fairfax, Virginia
  • Inova Fairfax Hospital — Falls Church, Virginia
  • VCU Massey Cancer Center at Stony Point — Richmond, Virginia
  • Virginia Commonwealth University/Massey Cancer Center — Richmond, Virginia
View on ClinicalTrials.gov →
Phase 2 Recruiting NIH

Testing Nivolumab and Ipilimumab Immunotherapy With or Without the Targeted Drug Cabozantinib in Recurrent, Metastatic, or Incurable Nasopharyngeal Cancer

This phase II trial tests how well nivolumab and ipilimumab immunotherapy with or without cabozantinib works in treating patients with nasopharyngeal cancer that has come back (after a period of improvement) (recurrent), has spread from wh…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05904080
Sites in Virginia:
  • VCU Massey Cancer Center at Stony Point — Richmond, Virginia
  • VCU Massey Comprehensive Cancer Center — Richmond, Virginia
View on ClinicalTrials.gov →
Phase 2 Recruiting NIH

A Study Using Nivolumab, in Combination With Chemotherapy Drugs to Treat Nasopharyngeal Carcinoma (NPC)

This phase II trial tests effects of nivolumab in combination with chemotherapy drugs prior to radiation therapy patients with nasopharyngeal carcinoma (NPC). Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06064097
Sites in Virginia:
  • University of Virginia Cancer Center — Charlottesville, Virginia
  • Children's Hospital of The King's Daughters — Norfolk, Virginia
  • VCU Massey Comprehensive Cancer Center — Richmond, Virginia
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements

Phase 1 dose escalation will determine the first cycle dose-limiting toxicities (DLTs), the maximum tolerated dose (MTD), the biologically effective dose and recommended Phase 2 dose (RP2D) of repotrectinib given to adult subjects with adv…

Sponsor: Turning Point Therapeutics, Inc.
NCT ID: NCT03093116
Sites in Virginia:
  • Local Institution - 2137 — Fairfax, Virginia
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

The Phase 2 monotherapy portion of this study is currently enrolling and will evaluate the efficacy and safety of PC14586 (INN rezatapopt) in participants with locally advanced or metastatic solid tumors harboring a TP53 Y220C mutation. Th…

Sponsor: PMV Pharmaceuticals, Inc
NCT ID: NCT04585750
Sites in Virginia:
  • Virginia Cancer Specialists — Fairfax, Virginia
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

First-in-Human Study of STX-478 as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors

Study STX-478-101 (LY4064809) is a multipart, open-label, phase 1/2 study evaluating the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of STX-478 (LY4064809) in participants with advanced solid tumors with…

Sponsor: Eli Lilly and Company
NCT ID: NCT05768139
Sites in Virginia:
  • USO-Virginia Cancer Specialists, PC — Fairfax, Virginia
View on ClinicalTrials.gov →
Phase 2 Recruiting Industry

A Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic Solid Tumors (IDeate-PanTumor02)

This study is designed to assess the efficacy and safety of ifinatamab deruxtecan (I-DXD) in the following tumor types: endometrial cancer (EC); head and neck squamous cell carcinoma (HNSCC); pancreatic ductal adenocarcinoma (PDAC); colore…

Sponsor: Daiichi Sankyo
NCT ID: NCT06330064
Sites in Virginia:
  • Virginia Cancer Specialists — Fairfax, Virginia
View on ClinicalTrials.gov →
Phase 2 Recruiting Industry

RRx-001 for Reducing Oral Mucositis in Patients Receiving Chemotherapy and Radiation for Head and Neck Cancer

The purpose of this study is to determine if RRx-001, which is added on to the cisplatin and radiation treatment, reduces the incidence of severe oral mucositis in patients with head and neck cancers. All patients in this study will receiv…

Sponsor: EpicentRx, Inc.
NCT ID: NCT05966194
Sites in Virginia:
  • University of Virginia — Charlottesville, Virginia
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations

This is a Phase 1/2, open-label, multicenter study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics and anti-tumor activity of TER-2013 in patients with advanced solid tumors harboring AKT/PI3K/PTEN pathway alteratio…

Sponsor: Terremoto Biosciences Inc.
NCT ID: NCT07109726
Sites in Virginia:
  • NEXT Oncology — Fairfax, Virginia
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

A Study to Evaluate ARV-806 in Adults With Advanced Cancer That Has the KRAS G12D Mutation

This is a study to evaluate the safety and potential anti-tumor activity of an investigational agent called ARV-806 in Adults with Advanced Cancer having a specific KRAS mutation. This is an open-label study which means that participants a…

Sponsor: Arvinas Inc.
NCT ID: NCT07023731
Sites in Virginia:
  • Clinical Trial Site — Fairfax, Virginia
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

A Study of Amivantamab Alone or in Addition to Other Treatment Agents in Participants With Head and Neck Cancer

The purpose of this study is to determine safety and preliminary efficacy of amivantamab monotherapy, amivantamab in addition to pembrolizumab, amivantamab in addition to paclitaxel and amivantamab in addition to pembrolizumab and carbopla…

Sponsor: Janssen Research & Development, LLC
NCT ID: NCT06385080
Sites in Virginia:
  • University of Virginia — Charlottesville, Virginia
  • Virginia Cancer Specialists — Fairfax, Virginia
View on ClinicalTrials.gov →
Phase 2 Recruiting Academic/Other

HPV DNA-Guided Radiotherapy De-intensification of Head and Neck Squamous Cell Carcinoma

The study will evaluate the safety and effectiveness of a lower than standard dose of radiation for definitive or adjuvant treatment of head and neck squamous cell carcinomas.

Sponsor: University of Virginia
NCT ID: NCT05962242
Sites in Virginia:
  • University of Virginia — Charlottesville, Virginia
  • Eastern Virginia Medical School — Norfolk, Virginia
  • Bon Secours — Richmond, Virginia
  • Virginia Commonwealth University — Richmond, Virginia
View on ClinicalTrials.gov →
Phase 2 Recruiting Industry

Phase II Trial of Neoadjuvant and Adjuvant IO102-IO103 and Pembrolizumab KEYTRUDA® in Patients With Resectable Tumors

This is a multicenter, multi-arm trial evaluating anti-tumor activity, safety, and immune infiltration of IO102-IO103 in combination with pembrolizumab KEYTRUDA® as neoadjuvant and post-surgery treatment. This proof-of-concept trial will i…

Sponsor: IO Biotech
NCT ID: NCT05280314
Sites in Virginia:
  • Massey Cancer Center — Richmond, Virginia
View on ClinicalTrials.gov →

Showing 25 of 46 trials with sites in Virginia. See all head and neck cancer trials →

Medical disclaimer: This page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-04-20